An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Brain cancer
- Focus Pharmacokinetics
- 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Jun 2016 Disease descriptor has been changed to brain tumor. Initially it was brain metastases, bladder-cancer, breast-cancer and non-small-cell-lung-cancer.
- 21 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 May 2018.